Published online before print May 26, 2005, doi: 10.1161/01.RES.0000171805.24799.fa
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Molecular Medicine |
Procoagulant Soluble Tissue Factor Is Released From Endothelial Cells in Response to Inflammatory Cytokines
From the Department of Cardiology and Pneumology (B.S., S.A., W.P., H.-P.S., U.R.), Charité –Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany; and the Institute of Pharmacy (B.S.), Free University of Berlin, Germany.
Correspondence to Dr Ursula Rauch, Medical Clinic II, Charité –Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany. E-mail ursula.rauch{at}charite.de
Inflammatory cytokines alter the hemostatic balance of endothelial cells (ECs). Alternatively spliced human tissue factor (asHTF), a soluble isoform of tissue factor (TF), has recently been detected in ECs, possibly contributing to procoagulability. Agonists regulating asHTF expression and release are yet unknown. This study examines the effect of TNF-
and IL-6 on the endothelial expression of both TF variants and delineates the impact of asHTF on the procoagulability of extracellular fluids. asHTF and TF mRNA were assessed by real-time PCR, and asHTF, TF, and tissue factor pathway inhibitor (TFPI) proteins by Western blot and fluorescence microscopy before and after stimulation with TNF- (10 ng/mL) or IL-6 (10 ng/L). The procoagulability of cell supernatant was analyzed by a chromogenic assay with or without phospholipid vesicles. We found asHTF mRNA to be maximally increased 10 minutes after TNF- and 40 minutes after IL-6 treatment (asHTF/GAPDH ratio 0.0223±0.0069 versus 0.0012±0.0006 for control, P<0.001 and 0.0022±0.0004 versus 0.0012±0.0007, P<0.05, respectively). Not only was asHTF increased, but also TFPI decreased after cytokine treatment. asHTF was found in the supernatant as early as 5 hours after TNF- stimulation, supporting factor Xa generation after relipidation (6.55±1.13 U versus 2.99±0.59 U in control supernatant, P<0.00001). Removal of asHTF from supernatants by immunoprecipitation diminished its procoagulability to baseline. The soluble TF isoform expressed and released from ECs in response to inflammatory cytokines becomes procoagulant in the presence of phospholipids. Thus, asHTF released from ECs is a marker for and a contributor to imbalanced hemostasis.
Key Words: tissue factor • procoagulability • cytokines • inflammation • endothelial cells
Related Article:
Circ. Res. 2005 96: 1217-1218.
This article has been cited by other articles:
 |
|
 |
|
  U. Johansson, I. Rasmusson, S. P. Niclou, N. Forslund, L. Gustavsson, B. Nilsson, O. Korsgren, and P. U. Magnusson Formation of Composite Endothelial Cell-Mesenchymal Stem Cell Islets: A Novel Approach to Promote Islet Revascularization Diabetes, September 1, 2008; 57(9): 2393 - 2401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kambas, M. M. Markiewski, I. A. Pneumatikos, S. S. Rafail, V. Theodorou, D. Konstantonis, I. Kourtzelis, M. N. Doumas, P. Magotti, R. A. DeAngelis, et al. C5a and TNF-{alpha} Up-Regulate the Expression of Tissue Factor in Intra-Alveolar Neutrophils of Patients with the Acute Respiratory Distress Syndrome J. Immunol., June 1, 2008; 180(11): 7368 - 7375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wu, M. J. Stevenson, J. M. Brown, E. A. Grunz, T. L. Strawn, and W. P. Fay C-Reactive Protein Enhances Tissue Factor Expression by Vascular Smooth Muscle Cells: Mechanisms and In Vivo Significance Arterioscler. Thromb. Vasc. Biol., April 1, 2008; 28(4): 698 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schouten, W. J. Wiersinga, M. Levi, and T. van der Poll Inflammation, endothelium, and coagulation in sepsis J. Leukoc. Biol., March 1, 2008; 83(3): 536 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Stahli, A. Breitenstein, A. Akhmedov, G. G. Camici, K. Shojaati, N. Bogdanov, J. Steffel, D. Ringli, T. F. Luscher, and F. C. Tanner Cardiac Glycosides Regulate Endothelial Tissue Factor Expression in Culture Arterioscler. Thromb. Vasc. Biol., December 1, 2007; 27(12): 2769 - 2776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhao, S. Zhou, and C.-K. Heng Impact of Serum Amyloid A on Tissue Factor and Tissue Factor Pathway Inhibitor Expression and Activity in Endothelial Cells Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1645 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Szotowski, S. Antoniak, P. Goldin-Lang, Q.-V. Tran, K. Pels, P. Rosenthal, V. Y. Bogdanov, H.-H. Borchert, H.-P. Schultheiss, and U. Rauch Antioxidative treatment inhibits the release of thrombogenic tissue factor from irradiation- and cytokine-induced endothelial cells Cardiovasc Res, March 1, 2007; 73(4): 806 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Stampfuss, P. Censarek, J. W. Fischer, K. Schror, and A.-A. Weber Rapid Release of Active Tissue Factor From Human Arterial Smooth Muscle Cells Under Flow Conditions Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): e34 - e37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Steffel, T. F. Luscher, and F. C. Tanner Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications Circulation, February 7, 2006; 113(5): 722 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chamorro and J. Hallenbeck The Harms and Benefits of Inflammatory and Immune Responses in Vascular Disease Stroke, February 1, 2006; 37(2): 291 - 293. [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ott Soluble Tissue Factor Emerges From Inflammation Circ. Res., June 24, 2005; 96(12): 1217 - 1218. [Full Text] [PDF]
|
|